Pay in 4 interest-free payments of $5.55 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
fj201800346R
Morris ER, Caswell SJ, Kunzelmann S, Arnold LH, Purkiss AG, Kelly G, et al
Tachibana, S
over whether they may increase the risk for CV problems," said Marc Pfeffer of Harvard Medical School and Brigham and Women's Hospital in the US, who presented the results of the ELIXA trial of Sanofi's glucagon-like peptide-1 (GLP-1) agonist Lyxumia (lixisenatide) at the ADA
We used mean changes from the time of drug discontinuation to the specified cutoff point of follow-up (week 4, week 8, week 12, week 20, week 26, and week 52) and standard deviations (SDs) extracted from published data when reported
US$ 22.18
US$ 25.57
US$ 20.56
US$ 26.64
US$ 23.27
US$ 20.17
